12:00 AM
 | 
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

ISIS-TTRRx regulatory update

Isis disclosed in its 2Q12 earnings that FDA granted Orphan Drug designation for ISIS-TTRRx to treat transthyretin (TTR) amyloidosis. The TTR...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >